What Gossamer Bio, Inc. does.

We are a clinical-stage biopharmaceutical company focused on the development and commercialization of seralutinib for the treatment of pulmonary hypertension, or PH, including pulmonary arterial hypertension, or PAH, and PH

associated with interstitial lung disease, or PH-ILD. Our goal is to be an industry leader in, and to enhance the lives of patients living with, PH. To accomplish this goal, we have assembled a deeply experienced and highly skilled group of industry veterans, scientists, clinicians and key opinion leaders from leading biotechnology and pharmaceutical companies, as well as leading academic centers from around the world. We intend to maintain a scientifically rigorous and inclusive corporate culture where employees strive to bring improved therapeutic options to patients.

Our founders and management team have held senior positions at leading biopharmaceutical companies and possess substantial experience and expertise across the spectrum of drug development and commercialization.

Revenue and profit, by fiscal year.

More on GOSS.

• Gossamer Bio, Inc. summary
• Gossamer Bio, Inc. financial statements
• Gossamer Bio, Inc. key metrics
• Gossamer Bio, Inc. health scores and style box
• Gossamer Bio, Inc. earnings
• Gossamer Bio, Inc. dividends
• Gossamer Bio, Inc. valuation
• Gossamer Bio, Inc. ownership and insiders
• Gossamer Bio, Inc. peers

Figures from Gossamer Bio, Inc.'s filings with the U.S. SEC, standardised automatically; prices are end-of-day closes. Not financial advice.